WaveMan
WaveMan · Company
SRZN · Surrozen, Inc./De
> Search tickers & screens ⌘K
LIVE
← All companies

SRZN Surrozen (SRZN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001824893
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
47
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · no price filed

What the filings say about SRZN

Insiders, 180 days
-$3.7M net sold
4 sellers · 0% of sales under a 10b5-1 plan

Surrozen insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Surrozen, Inc./DE insiders sold a net $3.7M of stock across 76 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
TCG Crossover GP II, LLC
SELL
2026-07-24 SECtraded 2026-07-22
162,500
$3.5M
+37.7%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 28.3% of the 574,054 shares held after it.
  • No other insider sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TCG Crossover GP II, LLC sold about $3.5M of SRZN on Jul 22, 2026, the largest insider sale at the company on our record; 47 funds added in the latest 13F quarter.
Li Yang
Exec. Vice President, Research
SELL
2026-05-05 SECtraded 2026-05-04
1,584
$52.8K
-20.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 5, 2026.
  • The trade is 9.2% of the 17,216 shares held after it.
  • 2 other insiders sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Exec. Vice President, Research Li Yang sold about $52.8K of SRZN on May 4, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 47 funds added in the latest 13F quarter.
Williams Charles O
Chief Operating Officer
SELL
2026-05-05 SECtraded 2026-05-04
2,036
$67.9K
-20.1%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jan 5, 2026.
  • The trade is 12.3% of the 16,571 shares held after it.
  • 2 other insiders sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Operating Officer Williams Charles O sold about $67.9K of SRZN on May 4, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 47 funds added in the latest 13F quarter.
Parker Craig C
Chief Executive Officer
SELL
2026-05-05 SECtraded 2026-05-04
4,524
$150.8K
-20.1%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 27.3% of the 16,553 shares held after it.
  • 2 other insiders sold within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Parker Craig C sold about $150.8K of SRZN on May 4, 2026, the largest insider sale at the company on our record; 2 other insiders sold within 30 days and 47 funds added in the latest 13F quarter.
TCG Crossover Fund II, L.P.
BUY
2026-03-25 SECtraded 2026-03-24
53,329
$1.3M
-2.6%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Mar 23, 2026.
  • -6.8% median (+1.2% mean) 90-day return after 6 previous buys.
  • The trade is 7.2% of the 736,547 shares held after it.
  • No other insider bought within 30 days.
  • 47 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider TCG Crossover Fund II, L.P. bought about $1.3M of SRZN on Mar 24, 2026; 47 funds added in the latest 13F quarter.
76 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 71 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$3.7M over 180 days
-$3.5M of it by a 10%+ holder
below 76% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
47 funds bought in last quarter
below 54% of Pharma & Biotech
Revenue
-67.4% year over year
below 84% of Pharma & Biotech
Margin
-6960.8% net margin
below 99% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
32.9% of the float short (float per yahoo 2026-10-26) · 1.5 days to cover · settled 2026-09-30
more than 92% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider selling stopped: no sales in 90 days after 4 in the prior 90
Why it matters
The absence is the signal: 4 sales in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch SRZN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+99.1%12M
-14%+40%+95%+149%2025-102025-122026-022026-042026-062026-082026-10 2026-07-22 · TCG Crossover GP II, LLC sold $3.5M2025-11-13 · Kutzkey Tim bought $2.1M2025-11-13 · COLUMN GROUP III GP, LP bought $2.1M2025-11-13 · Kutzkey Tim bought $1.9M2025-11-13 · COLUMN GROUP III GP, LP bought $1.9M2026-03-24 · TCG Crossover Fund II, L.P. bought $1.3M2026-03-13 · TCG Crossover Fund II, L.P. bought $440.8K2026-03-13 · TCG Crossover Fund II, L.P. bought $440.8K2025-12-05 · Kutzkey Tim bought $320.1K2025-12-05 · COLUMN GROUP III GP, LP bought $320.1K2025-12-05 · Kutzkey Tim bought $283.4K2025-12-05 · COLUMN GROUP III GP, LP bought $283.4K2026-02-11 · TCG Crossover Fund II, L.P. bought $209.4K2026-02-11 · TCG Crossover Fund II, L.P. bought $209.4K2026-03-23 · TCG Crossover Fund II, L.P. bought $189.5K2026-03-23 · TCG Crossover Fund II, L.P. bought $189.5K2026-01-20 · Column Group Opportunity III GP, LP bought $187.5K2026-01-20 · Kutzkey Tim bought $187.5K2026-01-20 · Column Group Opportunity III GP, LP bought $166.3K2026-01-20 · Kutzkey Tim bought $166.3K2026-01-06 · COLUMN GROUP III GP, LP bought $159.2K2026-01-06 · Kutzkey Tim bought $159.2K2026-03-12 · TCG Crossover Fund II, L.P. bought $154.6K2026-05-04 · Parker Craig C sold $150.8K2026-01-06 · COLUMN GROUP III GP, LP bought $141.2K2026-01-06 · Kutzkey Tim bought $141.2K2026-01-13 · Kutzkey Tim bought $130.9K2026-01-13 · TCG Opportunity III GP, LLC bought $130.9K2026-01-15 · Column Group Opportunity III GP, LP bought $125.4K2026-01-15 · Kutzkey Tim bought $125.4K2026-01-13 · Kutzkey Tim bought $116.0K2026-01-13 · TCG Opportunity III GP, LLC bought $116.0K2026-01-15 · Column Group Opportunity III GP, LP bought $111.2K2026-01-15 · Kutzkey Tim bought $111.2K2026-05-04 · Williams Charles O sold $67.9K2026-01-14 · Kutzkey Tim bought $58.5K2026-01-14 · TCG Opportunity III GP, LLC bought $58.5K2026-05-04 · Li Yang sold $52.8K2026-01-14 · Kutzkey Tim bought $51.9K2026-01-14 · TCG Opportunity III GP, LLC bought $51.9K2025-12-04 · Kutzkey Tim bought $48.4K2025-12-04 · COLUMN GROUP III GP, LP bought $48.4K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SRZN: institutional holders (13F)

13F holdings, latest reported quarter
Column Group LLC
1,916,950 sh
$49.7M
TCG Crossover Management, LLC
1,473,101 sh
$38.2M
Boxer Capital Management, LLC
1,172,349 sh
$27.0M
Kalehua Capital Management LLC
770,356 sh
$20.0M
MILLENNIUM MANAGEMENT LLC
683,079 sh
$17.7M

Congress trades in SRZN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SRZN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SRZN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$614.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$40.9K position · as of 2026-06-30
0.0%
Fidelity Small Cap Growth Index Fund
$178.3K position · as of 2026-06-30
0.0%
iShares Russell 2000 Growth ETF
$1.6M position · as of 2026-06-30
0.0%
PD Small-Cap Growth Index Portfolio
$15.5K position · as of 2026-06-30
0.0%
Voya VACS Index Series SC Portfolio
$15.2K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$2.8M
$4.8M
$1.4M
+140%
n/a
2024
$1.5M
$1.9M
$927.3K
+53%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows a net $3.7M sold by insiders over 180 days, 47 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

SRZN financials

Revenue growth
-67.4%
XBRL, annual
Net margin
-6960.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$11.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-2,885%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$35.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-304.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-43.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-10.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$3.5M$10.7M$0$12.5M
Operating income-$42.1M-$25.5M-$45.8M-$44.3M
Net income-$242.0M-$63.6M-$43.0M-$36.0M
EPS (diluted)-32.37-21.67-21.33-15.56
Operating cash flow-$30.2M-$17.6M-$40.4M-$44.1M
Cash$89.2M$34.6M$36.0M$24.7M
Buybacksn/an/a$0$2.6M
SEC XBRL, fiscal years, as known on 2026-10-28

SRZN Stock Sonar score 5/7 axes

Find similar shapesCompare

SRZN ranks highest on institutional and government (46th percentile) and risk and compliance (45th), and lowest on insider conviction (11th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
32
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-304.3% · 7 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-43.6% · 57 pct, sector of 576
Growth
16
Inputs
  • Revenue growth, YoY-67.4% · 16 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
11
Inputs
  • Net Form 4 buying (codes P and S), 180d-$3.7M · 22 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
46
Inputs
  • Funds adding, latest quarter47 · 46 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
45
Inputs
  • Short interest, % of float+32.9% · 3 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.9% · 88 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SRZN filings, in plain words

Are Surrozen insiders buying or selling SRZN?

In the 180 days to 2026-10-28, Surrozen insiders were net sellers, a net $3.7M across purchases and sales reported on Form 4, by 4 sellers.

Read the full summary

In the 180 days to 2026-10-28, Surrozen insiders were net sellers of SRZN, a net $3.7M across purchases and sales reported on Form 4 by 4 sellers. Most of that figure, $3.5M, came from a holder of 10% or more rather than an officer or director. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies